US âhumanitarian wavierâ will help deliver life-saving HIV medicines: UN
The UNAIDS has welcomed a move by the United States Secretary of State, Marco Rubio, to approve an âEmergency Humanitarian Waiverâ to allow.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The UNAIDS has welcomed a move by the United States Secretary of State, Marco Rubio, to approve an âEmergency Humanitarian Waiverâ to allow.
A US governmentâs decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s.
About one person every second or 42 million people each year are estimated to contract genital herpes infection worldwide, according to the World.
Malaria, HIV, and tuberculosis were among a list of 17 disease-causing pathogens where vaccines need to be developed as a priority to reduce.
HQ Team November 3, 2024: The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability.
Tuberculosis has emerged as the worldâs top infectious disease with about 8.2 million people newly diagnosed with the illness last year â the.
Merck & Co., Inc., and Gilead Sciences, Inc.âs investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.
Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.
About one in seven adolescents in the age group of 10-19 suffer from mental disorders such as depression and anxiety, according to the.
HIV vaccine trials conducted in Eastern and Southern Africa threw up surprising results when more infections were reported in the two vaccine groups.